Cargando…

Biotech in China 2021, at the beginning of the 14th five-year period (“145”)

ABSTRACT: As China assumes a more and more dominant role in global science, this mini-review attempts to provide a bird’s eye view on how the bio-digital revolution impacts China’s biosciences and bioindustry. Triggered by top-down political programs and the buildup of an impressive infrastructure i...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmid, Rolf D., Xiong, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088835/
https://www.ncbi.nlm.nih.gov/pubmed/33937929
http://dx.doi.org/10.1007/s00253-021-11317-8
Descripción
Sumario:ABSTRACT: As China assumes a more and more dominant role in global science, this mini-review attempts to provide a bird’s eye view on how the bio-digital revolution impacts China’s biosciences and bioindustry. Triggered by top-down political programs and the buildup of an impressive infrastructure in science, information technology, and education, China’s biomedical and MedTech industries prosper. Plant and animal breeding programs transform agriculture and food supply as much as the Internet of things, and synthetic biology offers new opportunities for the manufacturing of specialty chemicals within the Chinese version of a “bioeconomy.” It is already becoming apparent that the new five-year period “145” (2021–2025) will further emphasize emission control, bioenvironmental protection, and more supply of biomass-derived energy. This review identifies key drivers in China’s government, industry, and academia behind these developments and details many access points for deeper studies. KEY POINTS: Biotechnology in China. Biomedical technology. New five-year period.